R: Utility-Based Optimal Phase II/III Drug Development Planning

# Utility-Based Optimal Phase II/III Drug Development Planning

## Documentation for package ‘drugdevelopR’ version 1.0.2

- DESCRIPTION file
- User guides, package vignettes and other documentation
- Package NEWS
- Package README

## Help Pages

optimal_bias | Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results
optimal_bias_binary | Optimal phase II/III drug development planning when discounting phase II results with binary endpoint
optimal_bias_normal | Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint
optimal_binary | Optimal phase II/III drug development planning with binary endpoint
optimal_multiarm | Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint
optimal_multiarm_binary | Optimal phase II/III drug development planning for multi-arm programs with binary endpoint
optimal_multiarm_normal | Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint
optimal_multiple_normal | Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints
optimal_multiple_tte | Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints
optimal_multitrial | Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints
optimal_multitrial_binary | Optimal phase II/III drug development planning where several phase III trials are performed
optimal_multitrial_normal | Optimal phase II/III drug development planning where several phase III trials are performed
optimal_normal | Optimal phase II/III drug development planning with normally distributed endpoint
optimal_tte | Optimal phase II/III drug development planning with time-to-event endpoint